1. Home
  2. SCM vs ALXO Comparison

SCM vs ALXO Comparison

Compare SCM & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stellus Capital Investment Corporation

SCM

Stellus Capital Investment Corporation

HOLD

Current Price

$8.41

Market Cap

244.3M

Sector

Finance

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.10

Market Cap

205.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCM
ALXO
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
244.3M
205.9M
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
SCM
ALXO
Price
$8.41
$2.10
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$9.00
$3.50
AVG Volume (30 Days)
286.6K
626.9K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
14.22%
N/A
EPS Growth
N/A
26.36
EPS
0.06
N/A
Revenue
N/A
N/A
Revenue This Year
$0.33
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$141.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.83
$0.60
52 Week High
$14.85
$2.66

Technical Indicators

Market Signals
Indicator
SCM
ALXO
Relative Strength Index (RSI) 61.74 57.76
Support Level $7.93 $1.96
Resistance Level $8.59 $2.31
Average True Range (ATR) 0.35 0.14
MACD 0.16 -0.01
Stochastic Oscillator 97.60 89.66

Price Performance

Historical Comparison
SCM
ALXO

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: